Here's Why Shareholders May Want To Be Cautious With Increasing Oncternal Therapeutics, Inc.'s (NASDAQ:ONCT) CEO Pay Packet
Here's Why Shareholders May Want To Be Cautious With Increasing Oncternal Therapeutics, Inc.'s (NASDAQ:ONCT) CEO Pay Packet
Key Insights
主要见解
- Oncternal Therapeutics' Annual General Meeting to take place on 20th of June
- Salary of US$609.4k is part of CEO Jim Breitmeyer's total remuneration
- The overall pay is 44% above the industry average
- Over the past three years, Oncternal Therapeutics' EPS fell by 5.0% and over the past three years, the total loss to shareholders 92%
- Oncternal Therapeutics的年度股东大会将于6月20日举行
- 薪资US$609.4k是CEO Jim Breitmeyer的总薪酬的一部分
- 总薪酬超过行业平均水平44%
- 在过去3年中,Oncternal Therapeutics的EPS下降了5.0%,而在过去3年中,股东的总损失为92%
Shareholders of Oncternal Therapeutics, Inc. (NASDAQ:ONCT) will have been dismayed by the negative share price return over the last three years. Per share earnings growth is also poor, despite revenues growing. In light of this performance, shareholders will have a chance to question the board in the upcoming AGM on 20th of June, where they can impact on future company performance by voting on resolutions, including executive compensation. Here's our take on why we think shareholders might be hesitant about approving a raise at the moment.
Oncternal Therapeutics, Inc. (NASDAQ:ONCT)的股东对过去三年的股价表现感到失望。尽管收入增长,但每股收益增长缓慢。鉴于这种表现,股东将有机会在即将到来的6月20日股东大会上质询董事会,并在决议中投票,包括执行薪酬。以下是我们对股东可能为何在目前犹豫批准加薪的看法。
How Does Total Compensation For Jim Breitmeyer Compare With Other Companies In The Industry?
Jim Breitmeyer的总薪酬与其他行业公司相比如何?
According to our data, Oncternal Therapeutics, Inc. has a market capitalization of US$25m, and paid its CEO total annual compensation worth US$1.6m over the year to December 2023. We note that's a decrease of 34% compared to last year. While this analysis focuses on total compensation, it's worth acknowledging that the salary portion is lower, valued at US$609k.
根据我们的数据,Oncternal Therapeutics, Inc.的市值为美元25m,其CEO在截至2023年12月的一年内总薪酬价值为美元1.6m。我们注意到,这比去年下降了34%。虽然这项分析着重于总薪酬,但值得注意的是,薪资部分较低,仅为US$609k。
In comparison with other companies in the American Biotechs industry with market capitalizations under US$200m, the reported median total CEO compensation was US$1.1m. Accordingly, our analysis reveals that Oncternal Therapeutics, Inc. pays Jim Breitmeyer north of the industry median. Moreover, Jim Breitmeyer also holds US$272k worth of Oncternal Therapeutics stock directly under their own name.
与市值低于2亿美元的美国生物技术行业的其他公司相比,报告的中位数CEO总薪酬为美元1.1m。因此,我们的分析显示,Oncternal Therapeutics, Inc.支付给Jim Breitmeyer超过行业中位数。此外,Jim Breitmeyer还直接拥有价值272k美元的Oncternal Therapeutics股票。
Component | 2023 | 2022 | Proportion (2023) |
Salary | US$609k | US$580k | 38% |
Other | US$1.0m | US$1.9m | 62% |
Total Compensation | US$1.6m | US$2.4m | 100% |
组成部分 | 2023 | 2022 | 比例(2023) |
薪资 | US$609k | US$580k | 38% |
其他 | 100万美元 | 190万美元 | 62% |
总补偿 | US$1.6m | 240万美元 | 100% |
Speaking on an industry level, nearly 23% of total compensation represents salary, while the remainder of 77% is other remuneration. Oncternal Therapeutics pays out 38% of remuneration in the form of a salary, significantly higher than the industry average. If non-salary compensation dominates total pay, it's an indicator that the executive's salary is tied to company performance.
从行业层面上说,近23%的总薪酬代表薪资,而其余的77%是其他薪酬。Oncternal Therapeutics以薪资形式支付了38%的薪酬,远高于行业平均水平。如果不以薪资为主的补偿占据了总薪酬的主导地位,则表明高管薪资与公司业绩挂钩。
![ceo-compensation](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20240614/0-6b4562ef5b59225c0898ae8c4b3ffe95-0-7a13e5b39fb026d2d95576a2a45cb0ed.png/big)
A Look at Oncternal Therapeutics, Inc.'s Growth Numbers
Oncternal Therapeutics, Inc.的增长数字
Over the last three years, Oncternal Therapeutics, Inc. has shrunk its earnings per share by 5.0% per year. In the last year, its revenue is up 22%.
在过去的三年中,Oncternal Therapeutics,Inc的每股收益每年下降了5.0%。在过去的一年中,其营业收入增长了22%。
Investors would be a bit wary of companies that have lower EPS On the other hand, the strong revenue growth suggests the business is growing. In conclusion we can't form a strong opinion about business performance yet; but it's one worth watching. Looking ahead, you might want to check this free visual report on analyst forecasts for the company's future earnings..
投资者对低每股收益的公司会有些犹豫,而强劲的营业收入增长则表明公司正在增长。总之,我们无法对业务表现形成强烈的看法,但这是值得关注的。展望未来,您可能需要查看有关公司未来盈利的分析师预测的免费视觉报告。
Has Oncternal Therapeutics, Inc. Been A Good Investment?
Oncternal Therapeutics, Inc.是一个好的投资吗?
The return of -92% over three years would not have pleased Oncternal Therapeutics, Inc. shareholders. So shareholders would probably want the company to be less generous with CEO compensation.
在过去的三年中,-92%的回报肯定不会让Oncternal Therapeutics, Inc.的股东感到满意。因此,股东可能希望公司在CEO薪酬上不要太慷慨。
To Conclude...
总之...
The loss to shareholders over the past three years is certainly concerning and possibly has something to do with the fact that the company's earnings haven't grown. Shareholders will get the chance at the upcoming AGM to question the board on key matters, such as CEO remuneration or any other issues they might have and revisit their investment thesis with regards to the company.
过去三年内对股东的损失肯定令人担忧,可能与该公司的收益未增长有关。股东将在即将举行的股东大会上有机会质询董事会,例如CEO薪酬或其他问题,并重新审视他们对该公司的投资论点。
CEO compensation is an important area to keep your eyes on, but we've also need to pay attention to other attributes of the company. We did our research and identified 4 warning signs (and 1 which is significant) in Oncternal Therapeutics we think you should know about.
CEO薪酬是需要密切关注的重要领域,但我们还需要关注公司的其他特点。我们进行了调查,并确定了Oncternal Therapeutics的4个警告信号(和1个重要信号),我们认为您应该知道。
Of course, you might find a fantastic investment by looking at a different set of stocks. So take a peek at this free list of interesting companies.
当然,你可能会通过观察其他股票的不同涨跌幅来找到一笔不错的投资。所以,可以看一下这个有趣的公司的免费列表。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
对本文有反馈?关于内容有所顾虑?直接和我们联系。或电邮 editorial-team (at) simplywallst.com。
这篇文章是Simply Wall St的一般性文章。我们根据历史数据和分析师预测提供评论,只使用公正的方法论,我们的文章并不意味着提供任何金融建议。文章不构成买卖任何股票的建议,也不考虑您的目标或您的财务状况。我们的目标是带给您基本数据驱动的长期关注分析。请注意,我们的分析可能不考虑最新的价格敏感公司公告或定性材料。Simply Wall St没有任何股票头寸。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
对本文有反馈?关于内容有所顾虑?直接和我们联系。或者,也可以发送电子邮件至editorial-team@simplywallst.com